Research Reports

Key takeaways

Revenue declined 95.6% to $258K from $5.9M as grant revenue decreased due to exhausted BARDA funds for tebipenem HBr and lower qualifying expenses.

Operating loss improved 48.8% to -$7.5M from -$14.7M, reflecting lower personnel-related costs from reduced R&D headcount.

Net loss narrowed 48.1% to -$7.2M from -$13.9M, driven by cost savings following SPR206 program cessation announced in March 2025.

Diluted EPS improved 48% to -$0.13 from -$0.25, benefiting from overall expense reductions.

Operating cash flow turned positive at $15.9M versus -$4.0M prior year, supported by timing of inflows amid operating improvements.

Cash position funds operations into 2028 per current plan, despite history of significant operating losses.

Full analysis

Liquidity remains a focus, with cash and equivalents as of March 31, 2026 sufficient to fund operations and capital needs into 2028 under the current plan. This supports tebipenem HBr advancement via BARDA and potential GSK collaboration, despite risks from restricted capital access or rising borrowing costs in volatile markets. Investment activities prioritize principal preservation, liquidity, and income without excess risk. Investors should note ongoing expense pressures and loss trajectory, balanced by cost controls and cash runway extending through 2028.

SPRO · Spero Therapeutics, Inc.

Summary

Key takeaways

Full analysis